|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||228.20 - 234.41|
|52 Week Range||176.36 - 242.99|
|Beta (5Y Monthly)||0.63|
|PE Ratio (TTM)||27.42|
|Earnings Date||Jan. 26, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||260.97|
Vertex (VRTX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
A company that is capable of generating earnings well above its interest expense can withstand financial hardship. Companies such as ArcBest (ARCB), Advanced Micro Devices (AMD), AGCO Corporation (AGCO) and Vertex (VRTX) are sound enough to meet financial obligations.
New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving sales of Vertex's (VRTX) triple therapy cystic fibrosis drug, Trikafta/Kaftrio higher.